Sign In
Buy BCAB
$3.40
-0.130 (-3.68%)
At Close: Jun 03, 2026
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
06:45am, Monday, 18'th May 2026
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license
BioAtla Announces Share Consolidation
04:06pm, Tuesday, 31'st Mar 2026
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biolog
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
04:05pm, Tuesday, 31'st Mar 2026
Initiated a formal process to monetize assets Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
07:30am, Monday, 02'nd Mar 2026
SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biolog
BioAtla, Inc. (NASDAQ:BCAB) Sees Large Drop in Short Interest
04:10am, Sunday, 01'st Mar 2026
BioAtla, Inc. (NASDAQ: BCAB - Get Free Report) saw a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 2,697,341 shares, a decrease of 5
Brokerages Set BioAtla, Inc. (NASDAQ:BCAB) Target Price at $4.00
01:06am, Friday, 16'th Jan 2026
Shares of BioAtla, Inc. (NASDAQ: BCAB - Get Free Report) have earned an average recommendation of "Hold" from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One r
SAN DIEGO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Drop in Short Interest
05:22am, Monday, 29'th Dec 2025
BioAtla, Inc. (NASDAQ: BCAB - Get Free Report) saw a significant decline in short interest during the month of December. As of December 15th, there was short interest totaling 4,341,741 shares, a decl
Mirum Pharmaceuticals (NASDAQ:MIRM) & BioAtla (NASDAQ:BCAB) Financial Comparison
01:46am, Wednesday, 10'th Dec 2025
Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and BioAtla (NASDAQ: BCAB - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
12:25am, Friday, 21'st Nov 2025
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript
06:51pm, Thursday, 13'th Nov 2025
BioAtla, Inc. ( BCAB ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jay Short - Co-Founder, CEO & Chairman Sheri Lydick - Chief Commercial Officer Eric Sievers - Chief Medi
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
04:05pm, Thursday, 13'th Nov 2025
Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approv
— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with a
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
08:00am, Wednesday, 05'th Nov 2025
SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
